SOHAIL BAZEL: Open Payments
NPI 1225003353 · HIGH POINT, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$833 in 55 payments from 14 companies in 2025. Trend: 2023 $925 · 2024 $896 · 2025 $833
Food & beverage: $833
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $381 |
| AstraZeneca Pharmaceuticals LP | 4 | $64 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $51 |
| Novo Nordisk Inc | 3 | $50 |
| Collegium Pharmaceutical, Inc. | 3 | $48 |
| Ardelyx, Inc. | 2 | $44 |
| PFIZER INC. | 2 | $36 |
| Lilly USA, LLC | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Corcept Therapeutics | 1 | $27 |
Products named: QULIPTA, UBRELVY, VRAYLAR, JARDIANCE, Belbuca, IBSRELA, NURTEC ODT, MOUNJARO.
Industry payments across NC — which companies pay providers there.
